Layered inorganic nanocomposites: A promising carrier for 5-fluorouracil (5-FU)

被引:83
作者
Kevadiya, Bhavesh D. [1 ,4 ]
Patel, Tapan A. [2 ]
Jhala, Devendrasinh D. [2 ]
Thumbar, Rahul P. [3 ]
Brahmbhatt, Harshad [1 ]
Pandya, Maharshi P. [4 ]
Rajkumar, Shalini [4 ]
Jena, Prasant K. [4 ]
Joshi, Ghanshyam V. [1 ]
Gadhia, Pankaj K. [3 ]
Tripathi, C. B. [5 ]
Bajaj, Hari C. [1 ]
机构
[1] CSIR, Discipline Inorgan Mat & Catalysis, Cent Salt & Marine Chem Res Inst, Bhavnagar 364021, Gujarat, India
[2] Gujarat Univ, Dept Zool, Univ Sch Sci, Ahmadabad, Gujarat, India
[3] Veer Narmad S Gujarat Univ, Dept Biosci, Surat, Gujarat, India
[4] Nirma Univ, Inst Sci, Ahmadabad, Gujarat, India
[5] Govt Med Coll, Dept Pharmacol, Bhavnagar, Gujarat, India
关键词
Nanocomposites; Intercalation; Na+-clay; Controlled drug release; Genotoxicity; ADVANCED COLORECTAL-CANCER; DNA-DAMAGE; RELEASE; FLUOROURACIL; DELIVERY; THERAPY; MONTMORILLONITE; NANOPARTICLES; MECHANISMS;
D O I
10.1016/j.ejpb.2012.01.004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We report here the intercalation of 5-fluorouracil (5-FU), an anticancer drug in interlayer gallery of Na+ clay (Montmorillonite, MMT), with the assistance of biopolymer (chitosan, CS). The X-ray diffraction patterns, thermal and spectroscopic analyses indicated the drug intercalation into the clay interlayer space in support of CS and stabilized in the longitudinal monolayer by electrostatic interaction. In vitro drug release showed controlled release pattern. The genotoxic effect of drug was in vitro evaluated in human lymphocyte cell culture by comet assay, and results indicated significant reduction in DNA damage when drug was intercalated with clay and formulated in composites. The results of in vitro cell viability assay in cancer cells pointed at decreased toxicity of drug when encapsulated in Na+-clay plates than the pristine drug. In vivo pharmacokinetics, biodistribution, hepatotoxicity markers, e.g., SGPT and SGOT, and liver/testicular histology in rats showed plasma/tissue drug levels were within therapeutic window as compared to pristine drug. Therefore, drug-clay hybrid and composites can be of considerable value in chemotherapy of cancer with reduced side effects. (C) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码:91 / 101
页数:11
相关论文
共 50 条
  • [1] Effect of Skimmed Milk on the Absorption and Metabolism of 5-Fluorouracil (5-FU) in Animals
    Ahmad, Maqsood
    Ghumman, Shazia Akram
    Alamgeer
    Sharif, Tanveer
    Sher, Muhammad
    Abbas, Tahir
    IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH, 2012, 11 (01): : 69 - 75
  • [2] Investigation of the molecular and cellular effects of Shilajit on 5-fluorouracil (5-FU)-induced nephrotoxicity in rats
    Ezer, Mehmet
    Ozturkler, Melek
    Yildiz-Dalginli, Kezban
    Atakisi, Emine
    Beserer-Havadar, Hatice
    Atakisi, Onur
    IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES, 2025, 28 (05) : 565 - 574
  • [3] Protracted infusional 5-fluorouracil (5-FU) with bolus mitomycin in 5-FU-resistant colorectal cancer
    Chester, JD
    Dent, JT
    Wilson, G
    Ride, E
    Seymour, MT
    ANNALS OF ONCOLOGY, 2000, 11 (02) : 235 - 237
  • [4] Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine
    Chakrabarti, Sakti
    Sara, Jaskanwal
    Lobo, Ronstan
    Eiring, Rachel
    Finnes, Heidi
    Mitchell, Jessica
    Hartgers, Mindy
    Okano, Akiko
    Halfdanarson, Thorvardur
    Grothey, Axel
    CLINICAL COLORECTAL CANCER, 2019, 18 (01) : 52 - 57
  • [5] Relationship between pharmacokinetics of 5-FU in plasma and in saliva, and toxicity of 5-fluorouracil/folinic acid
    Jansman, FGA
    Coenen, JLLM
    De Graaf, JC
    Tobi, H
    Sleijfer, DT
    Brouwers, JRBJ
    ANTICANCER RESEARCH, 2002, 22 (6B) : 3449 - 3455
  • [6] Preliminary observations indicate variable patterns of plasma 5-fluorouracil (5-FU) levels during dose optimization of infusional 5-FU in colorectal cancer patients
    Kline, Christina Leah
    Sheikh, Hassan S.
    Scicchitano, Angelique
    Gingrich, Rebecca
    Beachler, Cheryl
    Finnberg, Niklas K.
    Liao, Jason
    Sivik, Jeffrey
    El-Deiry, Wafik S.
    CANCER BIOLOGY & THERAPY, 2011, 12 (07) : 557 - 568
  • [7] Effect of cholesterol on behavior of 5-fluorouracil (5-FU) in a DMPC lipid bilayer, a molecular dynamics study
    Khajeh, Aboozar
    Modarress, Hamid
    BIOPHYSICAL CHEMISTRY, 2014, 187 : 43 - 50
  • [8] SEQUENTIAL METHOTREXATE, 5-FLUOROURACIL (5-FU), AND HIGH-DOSE LEUCOVORIN VERSUS 5-FU AND HIGH-DOSE LEUCOVORIN VERSUS 5-FU ALONE FOR ADVANCED COLORECTAL-CANCER - A MULTIINSTITUTIONAL RANDOMIZED TRIAL
    ABAD, A
    GARCIA, P
    GRAVALOS, C
    TUSQUETS, I
    FONT, A
    PEREZ, G
    CORTESFUNES, H
    FABREGAT, X
    BARNADAS, A
    ROSELL, R
    CANCER, 1995, 75 (06) : 1238 - 1244
  • [9] Effect of viscous additives on the absorption and hepatic disposition of 5-fluorouracil (5-FU) after application to liver surface in rats
    Kodama, Yukinobu
    Horishita, Miyuki
    Fumoto, Shintaro
    Mine, Toyoharu
    Miyamoto, Hirotaka
    Yoshikawa, Naoki
    Hirata, Haruna
    Sasaki, Hitoshi
    Nakamura, Junzo
    Nishida, Koyo
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2012, 64 (10) : 1438 - 1444
  • [10] A COMPARISON OF 5-FLUOROURACIL(5-FU) LEUCOVORIN WITH OTHER CURRENT CHEMOTHERAPEUTIC REGIMENS IN THE TREATMENT OF METASTASIZING COLORECTAL-CANCER
    BAUR, M
    SCHLAPPACK, O
    HAVELEC, L
    MADER, R
    MAROSI, C
    SCHEITHAUER, W
    DITTRICH, C
    WIENER KLINISCHE WOCHENSCHRIFT, 1991, 103 (11) : 332 - 339